Methods for treating muscle diseases and disorders
View Patent ↗The invention relates to methods of treating diseases and disorders of the muscle tissues in a vertebrate by the administration of compounds which bind the p185 erbB2 receptor. These compounds are found to cause increased differentiation and survival of cardiac, skeletal and smooth muscle.
1. A method of increasing mitogenesis of a mammalian muscle cell, said method comprising administering to said muscle cell a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 414.
2. A method of increasing mitogenesis of a mammalian muscle cell, said method comprising administering to said muscle cell a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 415.
3. A method of increasing the mitogenesis of a mammalian muscle cell, said method comprising administering to said muscle cell a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 416.
4. A method of increasing the mitogenesis of a mammalian muscle cell, said method comprising administering to said muscle cell a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 417.
5. A method of increasing the mitogenesis of a mammalian muscle cell, said method comprising administering to said muscle cell a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 418.
6. A method of increasing the mitogenesis of a mammalian muscle cell, said method comprising administering to said muscle cell a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 419.
7. A method of increasing myotube formation, myotube survival, or the induction of a muscle developmental program which specifies components of the muscle contractile apparatus of a muscle cell in a mammal in need thereof, said method comprising administering to said mammal a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 414.
8. A method of increasing muscle cell survival in a mammal in need thereof, said method comprising administering to said mammal a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 414.
9. A method of increasing myotube formation, myotube survival, or the induction of a muscle developmental program which specifies components of the muscle contractile apparatus of a muscle cell in a mammal in need thereof, said method comprising administering to said mammal a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 415.
10. A method of increasing muscle cell survival in a mammal in need thereof, said method comprising administering to said mammal a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 415.
11. A method of increasing myotube formation, myotube survival, or the induction of a muscle developmental program which specifies components of the muscle contractile apparatus of a muscle cell in a mammal in need thereof, said method comprising administering to said mammal a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 416.
12. A method of increasing muscle cell survival in a mammal in need thereof, said method comprising administering to said mammal a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 416.
13. A method of increasing myotube formation, myotube survival, or the induction of a muscle developmental program which specifies components of the muscle contractile apparatus of a muscle cell in a mammal in need thereof, said method comprising administering to said mammal a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 417.
14. A method of increasing muscle cell survival in a mammal in need thereof, said method comprising administering to said mammal a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 417.
15. A method of increasing myotube formation, myotube survival, or the induction of a muscle developmental program which specifies components of the muscle contractile apparatus of a muscle cell in a mammal in need thereof, said method comprising administering to said mammal a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 418.
16. A method of increasing muscle cell survival in a mammal in need thereof, said method comprising administering to said mammal a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 418.
17. A method of increasing myotube formation, myotube survival, or the induction of a muscle developmental program which specifies components of the muscle contractile apparatus of a muscle cell in a mammal in need thereof, said method comprising administering to said mammal a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 419.
18. A method of increasing muscle cell survival in a mammal in need thereof, said method comprising administering to said mammal a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 419.
19. A method of increasing muscle cell mitogenesis in a mammal in need thereof, said method comprising administering to said mammal a polypeptide comprising an EGF-like domain selected from the group consisting of the amino acid sequence of SEQ ID NO: 151, the amino acid sequence of SEQ ID NO: 152, amino acids 362-411 of SEQ ID NO: 170, and the amino acid sequence encoded by nucleic acids 161-310 of SEQ ID NO: 150, in an amount effective for increasing said muscle cell mitogenesis.
20. A method of increasing muscle cell survival in a mammal in need thereof, said method comprising administering to said mammal a polypeptide comprising an EGF-like domain selected from the group consisting of the amino acid sequence of SEQ ID NO: 151, the amino acid sequence of SEQ ID NO: 152, amino acids 362-41 of SEQ ID NO: 170, and the amino acid sequence encoded by nucleic acids 161-310 of SEQ ID NO: 150, in an amount effective for increasing said muscle cell survival.
21. A method of increasing myotube formation, myotube survival, or the induction of a muscle developmental program which specifies components of the muscle contractile apparatus of a cardiac or smooth muscle cell in a mammal in need thereof, said method comprising administering to said mammal a polypeptide comprising an EGF-like domain selected from the group consisting of the amino acid sequence of SEQ ID NO: 151, the amino acid sequence of SEQ ID NO: 152, amino acids 362-411 of SEQ ID NO: 170, and the amino acid sequence encoded by nucleic acids 161-310 of SEQ ID NO: 150, in an amount effective for increasing said myotube formation, myotube survival, or differentiation of said cardiac or smooth muscle cell.
22. The method of claim 1 , 2 , 3 , 4 , 5 , or 6 , wherein said muscle cell is from a mammal having a pathophysiological condition of the musculature.
23. The method of claim 1 , 2 , 3 , 4 , 5 , or 6 , wherein said administering is in vivo.
24. A method of increasing muscle cell mitogenesis in a mammal in need thereof, said method comprising administering to said mammal a polypeptide comprising an EGF-like domain selected from the group consisting of the amino acid sequence of SEQ ID NO: 151, the amino acid sequence of SEQ ID NO: 152, amino acids 362-411 of SEQ ID NO: 170, and the amino acid sequence encoded by nucleic acids 161-310 of SEQ ID NO: 150, wherein said polypeptide binds the p185 erbB2 receptor, said administering in an amount effective for increasing said muscle cell mitogenesis.
25. A method of increasing muscle cell survival in a mammal in need thereof, said method comprising administering to said mammal a polypeptide comprising an EGF-like domain selected from the group consisting of the amino acid sequence of SEQ ID NO: 151, the amino acid sequence of SEQ ID NO: 152, amino acids 362-411 of SEQ ID NO: 170, and the amino acid sequence encoded by nucleic acids 161-310 of SEQ ID NO: 150, wherein said polypeptide binds the p185 erbB2 receptor, said administering in an amount effective for increasing said muscle cell survival.
26. A method of increasing differentiation of a mammalian muscle cell in a mammal in need thereof, said method comprising administering to said mammal a polypeptide comprising an EGF-like domain selected from the group consisting of the amino acid sequence of SEQ ID NO: 151, the amino acid sequence of SEQ ID NO: 152,